Recent Updates
Recently added Catalysts

MEDI5884

Phase 2

Stable Coronary Heart Disease | Small molecule | Cardiovascular |AstraZeneca PLC|Last Updated: Mar 23, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment133
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03351738A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart DiseasePHASE2 COMPLETED 133Dec 13, 2017Nov 9, 2018Mar 23, 202023 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Day 1 (Baseline) through Day 241

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Number of Participants With Clinically Important Changes in Electrocardiograms (ECGs) From Baseline
Day 1 (Baseline) through Day 241

Number of participants with clinically important changes in ECGs from baseline are reported. Clinically important changes in ECGs is defined as any clinical significant difference in heart rate, RR interval, PR interval, QRS, and QT intervals from the primary lead of the digital 12-lead ECG from baseline.

Number of Participants With Clinically Important Changes in Vital Signs From Baseline
Day 1 (Baseline) through Day 241

Number of participants with clinically important changes in vital signs from baseline are reported. Vital signs measurements were obtained after the participant had rested in the supine position for at least 10 minutes at the recording time. Clinically important changes in vital signs from baseline is defined as any clinical significant difference in the vital sign parameters (blood pressure, heart rate, body temperature, and respiratory rate) from baseline.

Number of Participants With Clinically Important Changes in Laboratory Parameters From Baseline
Day 1 (Baseline) through Day 241

Number of participants with clinically important changes in laboratory parameters from baseline are reported. Clinically important changes in laboratory parameters is defined as any clinical significant difference in analysis of serum chemistry, hematology, and urine from baseline.

Number of Participants With Clinically Important Changes in Physical Examinations From Baseline
Day 1 (Baseline) through Day 241

Number of participants with clinically important changes in physical examinations from baseline are reported. Clinically important changes in physical examinations is defined as any clinical significant difference in general appearance, head, ears, eyes, nose, throat, neck, skin, heart, lung, abdomen, musculoskeletal system, endocrine system, nervous system, height, and weight from baseline.

Secondary Endpoints
Change From Baseline in Apolipoprotein B
Day 1 (Baseline), and Days 31, 61, and 91
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)
Day 1 (Baseline), and Days 31, 61, and 91
Area Under the Concentration-time Curve for 30 Days (AUC30d) After the Last Dose of MEDI5884
Day 61 (pre-dose), and on Days 64, 68, 71, and 91
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PlaceboPLACEBO_COMPARATORParticipants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
MEDI5884 50 mgEXPERIMENTALParticipants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
MEDI5884 100 mgEXPERIMENTALParticipants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
MEDI5884 200 mgEXPERIMENTALParticipants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
MEDI5884 350 mgEXPERIMENTALParticipants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
MEDI5884 500 mgEXPERIMENTALParticipants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.
Interventions
NameTypeDescription
MEDI5884DRUGParticipants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
PlaceboDRUGParticipants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
Unlock Study Design Details
Eligibility Criteria
Age Range45 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites23

Inclusion Criteria: * Diagnosis of stable coronary heart disease prior to screening * Currently receiving high intensity statin(s) Exclusion Criteria: * Unstable cardiovascular conditions * Any planned arterial revascularizations * Fasting Laboratory values at screening: Triglycerides \> 500 mg/d...

Countries:United States
Unlock Eligibility Criteria